Подходы к диагностике и лечению гастроэзофагеальной рефлюксной болезни в сочетании с дуоденогастроэзофагеальным рефлюксом


Самсонов А.А., Голубев Н.Н., Андреев Н.Г., Одинцова А.Н.

ГОУ ВПО “Московский государственный медико-стоматологический университет” Минздравсоцразвития России, Москва, Клиника “Ниармедик”, Москва
В статье рассматривается роль билиарного рефлюкса в патогенезе гастроэзофагеальной рефлюксной болезни. На основе результатов экспериментальных и клинических исследований показано клиническое значение дуоденогастроэзофагеального рефлюкса при различных формах этого заболевания. Освещены современные подходы к лечению данной категории пациентов с применением комплексной терапии на основе ингибиторов протонной помпы и прокинетиков.

Литература


1. Лазебник Л.Б., Машарова А.А., Бордин Д.С. и др. Многоцентровое исследование
“Эпидемиология гастроэзофагеальной рефлюксной болезни в России (МЭГРЕ): первые итоги” // Эксперимент. и клин. гастроэнтерол. 2009. № 6. С. 4–12.
2. Tack J. Review article: role of pepsin and bile in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005;(1):48–54.
3. Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond
well to proton pump inhibitors. Curr Opin Gastroenterol 2010;26(4):367–78.
4. Orlando RC, Bozymski EM. Heartburn in pernicious anemia – a consequence of bile reflux. N Engl J Med 1973;289:522–23.
5. Matikainen M, Laatikainen T, Kalima T, et al. Bile acid composition and esophagitis after total gastrectomy. Am J Surg 1982;143:196–98.
6. Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in oesophageal mucosal injury: a review of animal and human studies. Gastroenterology 1995;108:1897–907.
7. Farre R, Fornari F, Blondeau K, et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 2010;59:164–69.
8. Bateson MC, Hopwood D, Milne G, Bouchier IA. Oesophageal epithelial ultrastructure after incubation with gastrointestinal fluids and their components. J Pathol 1981;133:33–51.
9. Souza RF, Huo X, Mittal V, et al.Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 2009;137:1776–84.
10. McQuaid KR, Laine L, Fennerty MB, et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther 2011;34:146–65.
11. Hong J, Behar J, Wands J, et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma. Gut 2010;59:170–80.
12. Nehra D, Howell P, Williams CP, et al. Toxic bile acids in gastro-oesophageal reflux disease: influence
of gastric acidity. Gut 1999;44:598–602.
13. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastrooesophageal reflux monitoring: review and
consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004;53:1024–31.
14. Boecxstaens V, Bisschops R, Blondeau K, et al. Modulation of the postprandial acid and bile pockets at the gastro-oesophageal junction by drugs that affect gastric motility. Aliment Pharmacol Ther 2011;33:1370–77.
15. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline
reflux in gastro-oesophageal reflux disease.Aliment Pharmacol Ther 2010;32:334–43.
16. Champion G, Richter JE, Vaezi MF, et al.Duodeno-gastro-oesophageal reflux: relations hip to pH and importance in Barrett’s oesophagus. Gastroenterology 1994;107:747–54.
17. Pace F, Sangaletti O, Pallotta S, et al. Biliary reflux and nonacid reflux are two distinct phenomena:
a comparison between 24-h multichannel intraesophageal impedance and bilirubin monitoring.
Scand J Gastroenterol 2007;42:1031–39.
18. Yumiba T, Kawahara H, Nishikawa K, et al. Impact of esophageal bile exposure on the genesis of reflux esophagitis in the absence of gastric acid after total gastrectomy. Am J Gastroenterol 2002;97:1647–52.
19. Wilmer A, Tack J, Frans E, et al. Duodeno-gastrooesophageal reflux and oesophageal mucosal injury in mechanically ventilated patients. Gastroenterology 1999;116:1293–99.
20. Xu X, Li Z, Zou D, et al. Role of duodenogastroesophageal reflux in the pathogenesis of esophageal mucosal injury and gastroesophageal reflux symptoms. Can J Gastroenterol 2006;20(2):91–4.
21. Tack J, Bisschops R, Koek G, et al. Dietary restrictions during ambulatory monitoring of duodeno-gastro-oesophageal reflux. Dig Dis Sci 2003;48:1213–30.
22. Oh DS, Hagen JA, Fein M, et al. The impact of reflux composition on mucosal injury and esophageal function. Journal of Gastrointestinal Surgery 2005;10:87–797.


23. Kunsch S, Neesse A, Huth J, et al. Increased duodenogastro-esophageal reflux (DGER) in symptomatic
GERD patients with a history of cholecystectomy. Z Gastroenterol 2009;47:744–48.
24. Wolfgarten E, Putz B, Holscher AH, Bollschweiler E. Duodeno-gastric-esophageal reflux – what is pathologic? Comparison of patients with Barrett’s esophagus and age-matched volunteers. J Gastrointest Surg 2007;11:479–86.
25. Koek GH, Sifrim D, Lerut T, et al. Multivariate analysis of the association of acid and duodenogastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett’s oesophagus. Gut 2008;57:1056–64.
26. Marshall RE, Anggiansah A, Owen WA, Owen WJ. The relationship between acid and bile reflux
and symptoms in gastro-oesophageal reflux disease. Gut 1997;40:182–87.
27. Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastro-oesophageal reflux in symptomatic GERD. Am J Gastroenterol 2001;96:2033–40.
28. Hoffman I, Tertychnyy A, Ectors N, et al Duodenogastro-Esophageal Reflux in Children with Refractory Gastro-Esophageal Reflux Disease. The Journal of Pediatrics 2007;151:307–11.
29. Karamanolis G, Vanuytsel T, Sifrim D, et al. Yield of 24-hour esophageal pH and bilitec monitoring
in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008;53:2387–93.
30. Gasiorowska A, Navarro-Rodriguez T, Wendel C, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux betweenpatients who failed to respond and those
who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009;104:2005–13.
31. Hershcovici T, Jha LK, Cui HJ, et al. Night-time intra-oesophageal bile and acid: a comparison between gastro-oesophageal reflux disease patients who failed and those who were treated successfully with a proton pump inhibitor. Alimentary Pharmacology & Therapeutics 2011;33:837–44.
32. Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastrooesophageal reflux disease. Aliment Pharmacol Ther 2006;24(2):10–6.
33. Huo X, Zhang HY, Zhang X, et al. Omeprazole Blocks Secretion of the Inflammatory Cytokine IL-8 in Esophageal Squamous Epithelial Cells Exposed to Acid and Bile Salts: A Potential Anti-Inflammatory Effect of PPIs Independent of Acid Inhibition. Abstract 1063 Presented at Digestive Disease Week, 2010.
34. Marshall RE, Anggiansah A, Manifold DK, et al.Effect of omeprazole 20 mg twice daily on duodenogastric
and gastro-osophageal bile reflux in barrett’s esophagus. Gut 1998;43:603–06.
35. Netzer P, Gut A, Brundler R, et al. Influence of pantoprazole on oesophageal motility, and bile
and acid reflux in patients with oesophagitis. Aliment Pharmacol Ther 2001;15:1375–84.
36. Menges M, Muller M, Zeitz M. Increased acid and bile reflux in Barrett’s esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. The Am J of Gastroenterol 2001;96:331–37.
37. Todd JA, Basu KK, De Caestecker JS. Normalization of oesophageal pH does not guarantee control
of duodenogastro-oesophageal reflux in Barrett’s oesophagus. Aliment Pharmacol Ther 2005;21:969–75.
38. Буеверов А.О., Лапина Т.Л. Дуоденогастроэзофагеальный рефлюкс как причина рефлюкс эзофагита // Фарматека 2006. № 1. С. 22–7.
39. Ивашкин В.Т., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике // РМЖ 2003. № 2. С. 43–8.
40. Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acidrelated
diseases. Therapeutics and Clinical Risk Management 2007;3:363–79.
41. Koek GH, Sifrim D, Lerut T, et al. The effect of the GABAb agonist baclofen in patients with
symptoms and duodenogastro-esophageal reflux refractory to proton pump inhibitors. Gut 2003;10:1397–402.
42. Scarpellini E, Vos R, Blondeau K, et al. The effects of itoprid on esophageal motility and lower
esophageal sprinter function in man. Aliment Pharmacol Ther 2011;33:99–105.
43. Лапина Т.Л., Картавенко И.М. Урсодеоксихолевания кислота: влияние на слизистую оболочку верхних отделов желудочно-кишечного тракта // Росс. журн. гастроэнтерол., гепатол., колопроктол. 2007. № 6. С. 51–7.


Об авторах / Для корреспонденции


Самсонов Алексей Андреевич – доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней и гастроэнтерологии ГОУ ВПО “Московский государственный медико-стоматологический университет” Минздравсоцразвития РФ. e-mail: aleksey.samsonov@gmail.com;
Голубев Николай Николаевич – кандидат медицинских наук, врач-гастроэнтеролог и эндоскопист клиники “Ниармедик”. e-mail: nngolubev@mail.ru;
Андреев Николай Германович – кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней и гастроэнтерологии ГОУ ВПО “Московский государственный медико-стоматологический университет” Минздравсоцразвития РФ.
Одинцова Анастасия Николаевна – кандидат медицинских наук, ассистент кафедры пропедевтики внутренних болезней и гастроэнтерологии ГОУ ВПО “Московский государственный медико-стоматологический университет” Минздравсоцразвития РФ.


Похожие статьи


Бионика Медиа